These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10924734)

  • 21. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum lipoproteins in acromegaly before and 6-15 months after transsphenoidal adenomectomy.
    Oscarsson J; Wiklund O; Jakobsson KE; Petruson B; Bengtsson BA
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):603-8. PubMed ID: 7828349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is the acromegalic cardiomyopathy reversible? Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance.
    Colao A; Cuocolo A; Marzullo P; Nicolai E; Ferone D; Della Morte AM; Pivonello R; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1551-7. PubMed ID: 11297582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum apolipoprotein(a) correlates with growth hormone levels in Chinese patients with acromegaly.
    Lam KS; Pang RW; Janus ED; Kung AW; Wang CC
    Atherosclerosis; 1993 Dec; 104(1-2):183-8. PubMed ID: 8141841
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion.
    Rio GD; Velardo A; Mascadri C; Zalteri G; Papi G; Menozzi R; Giustina A
    Eur J Endocrinol; 2000 Feb; 142(2):179-86. PubMed ID: 10664528
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins.
    Pazos F; Alvarez JJ; Rubiés-Prat J; Varela C; Lasunción MA
    J Clin Endocrinol Metab; 1995 Feb; 80(2):562-6. PubMed ID: 7852521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
    Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
    Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of low-density lipoprotein buoyant density and cholesterol content on the formation of lipoprotein(a) particles.
    Becker L; Gabel BR; Spencer CA; Marcovina SM; Koschinsky ML
    Clin Exp Med; 2001 Jun; 1(2):121-5. PubMed ID: 11699729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of atorvastatin on lipid profile and non-traditional cardiovascular risk factors in diabetic patients on hemodialysis.
    Navarro JF; Mora C; Muros M; García-Idoate G
    Nephron Clin Pract; 2003; 95(4):c128-35. PubMed ID: 14694274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.
    Berneis K; Jeanneret C; Muser J; Felix B; Miserez AR
    Metabolism; 2005 Feb; 54(2):227-34. PubMed ID: 15690318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth hormone isoforms in acromegalic patients before and after treatment with octreotide LAR.
    Lima GA; Wu Z; Silva CM; Barbosa FR; Dias JS; Schrank Y; Strasburger CJ; Gadelha MR
    Growth Horm IGF Res; 2010 Apr; 20(2):87-92. PubMed ID: 19884028
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oxidation of lipoprotein(a) and low density lipoprotein containing density gradient ultracentrifugation fractions.
    Kleinveld HA; Duif PF; Pekelharing HL; van Rijn HJ
    Biochim Biophys Acta; 1996 Sep; 1303(1):15-21. PubMed ID: 8816848
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating adiponectin levels and cardiovascular risk factors in acromegalic patients.
    Ronchi CL; Corbetta S; Cappiello V; Morpurgo PS; Giavoli C; Beck-Peccoz P; Arosio M; Spada A
    Eur J Endocrinol; 2004 May; 150(5):663-9. PubMed ID: 15132722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholesteryl ester transfer activity in liver disease and cholestasis, and its relation with fatty acid composition of lipoprotein lipids.
    Iglesias A; Arranz M; Alvarez JJ; Perales J; Villar J; Herrera E; Lasunción MA
    Clin Chim Acta; 1996 Apr; 248(2):157-74. PubMed ID: 8740580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LDL size distribution in relation to insulin sensitivity and lipoprotein pattern in young and healthy subjects.
    Ambrosch A; Mühlen I; Kopf D; Augustin W; Dierkes J; König W; Luley C; Lehnert H
    Diabetes Care; 1998 Dec; 21(12):2077-84. PubMed ID: 9839097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Lp(a) rather than integrally-bound apo(a) with triglyceride-rich lipoproteins of human subjects.
    Marcoux C; Lussier-Cacan S; Davignon J; Cohn JS
    Biochim Biophys Acta; 1997 Jun; 1346(3):261-74. PubMed ID: 9219911
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low density lipoprotein particle size in hypopituitary adults receiving conventional hormone replacement therapy.
    O'Neal D; Hew FL; Sikaris K; Ward G; Alford F; Best JD
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2448-54. PubMed ID: 8675559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.